MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Impact of chronic LD treatment on metabolism, blood flow and blood-brain barrier permeability in the 6-OHDA rat model

    R.P. Lerner, Z. Bimpisidis, V. Jourdain, T. Chaly, M. Hellman, K. Graf, V. Dhawan, S. Dewey, A. Cenci, D. Eidelberg (Manhasset, NY, USA)

    Objective: To determine the effects of chronic LD treatment and induction of dyskinesias on cerebral metabolism, blood flow and blood-brain barrier permeability in 6-OHDA rat…
  • 2016 International Congress

    Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease

    T. Willows, N. Dizdar, D. Nyholm, H. Widner, P. Grenholm, U. Schmiauke, A. Urbom, K. Groth, J. Larsson, J. Permert, S. Kjellander (Huddinge, Sweden)

    Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…
  • 2016 International Congress

    Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study

    P. Havránková, J. Klempír, M. Fialová, A. Rezková, J. Petrtýl, V. Capek, E. Ruzicka, J. Roth, R. Jech (Praha, Czech Republic)

    Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…
  • 2016 International Congress

    Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations

    R. Pahwa, P. LeWitt, A. Corbin, R. Batycky, H. Murck (Kansas City, KS, USA)

    Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…
  • 2016 International Congress

    Impact of comorbidities and compliance initiatives in management of patients with early Parkinson’s disease

    A.V. Shalaeva, N.A. Dadabaeva, R.M. Allanov, M.B. Bozorboev, E. Shalaeva (Tashkent, Uzbekistan)

    Objective: To evaluate the impact of comorbidities and compliance iniciatives on treatment efficacy in patients with Parkinson's disease. Methods: In the year 2014 we included…
  • 2016 International Congress

    The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease

    J.E. Ferrario, S. Sanz-Blasco, M. Bordone, A. Damianich, A. Bernardi, G. Gomez, I. Taravini, E. Avale, O. Gershanik (Buenos Aires, Argentina)

    Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
  • 2016 International Congress

    Levodopa impairs learning in healthy young adults: Implications for Parkinson’s disease

    P.A. MacDonald, A. Vo, K.N. Seergobin (London, ON, Canada)

    Objective: The objective was to investigate the effect of dopaminergic therapy on healthy young adults to test the dopamine overdose hypothesis. Background: Dopaminergic therapy improves…
  • 2016 International Congress

    Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

    Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
  • 2016 International Congress

    Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study

    A. Merola, A.J. Espay, A. Romagnolo, A. Bernardini, M. Rosso, K.J. Espay, L. Rizzi, M. Zibetti, M. Lanotte, L. Lopiano (Torino, Italy)

    Objective: To analyze the long-term retrospective data of patients treated with Levodopa/carbidopa intestinal gel infusion (LCIG) and subthalamic nucleus deep brain stimulation (STN-DBS) in two…
  • 2016 International Congress

    Status of NPF-QII after six years: Updates to the dataset

    F. Cubillos, E.C. Nelson, T. Simuni, C. Marras, M. Rafferty, T. Davis, P. Schmidt (Miami, FL, USA)

    Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…
  • « Previous Page
  • 1
  • …
  • 66
  • 67
  • 68
  • 69
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley